Urokinase receptor cleavage: A crucial step in fibroblast-to-myofibroblast differentiation

Molecular Biology of the Cell

Volumn 18, Issue 7, 2007, Pages 2716-2727

  Bernstein, Audrey M ^a   Twining, Sally S ^b   Warejcka, Debra J ^b   Tall, Edward ^a   Masur, Sandra K ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; COMPLEMENTARY DNA; GROWTH FACTOR; PROTEINASE; PROTEINASE INHIBITOR; UROKINASE; UROKINASE RECEPTOR;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FIBROBLAST; GENE EXPRESSION; GENE OVEREXPRESSION; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; WOUND; WOUND CLOSURE; WOUND HEALING;

ACTINS; CELL DIFFERENTIATION; CORNEA; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; HEPATOCYTES; HUMANS; LUNG; MYOBLASTS; OLIGOPEPTIDES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, CELL SURFACE; STRESS FIBERS; SULFONES; TRANSFORMING GROWTH FACTOR BETA1; URINARY PLASMINOGEN ACTIVATOR;

EID: 34347384693     PISSN: 10591524     EISSN: None     Source Type: Journal    
DOI: 10.1091/mbc.E06-10-0912     Document Type: Article

References (59)

1. Abe, M., Harpel, J. G., Metz, C. N., Nunes, I., Loskutoff, D. J., and Rifkin, D. B. (1994). An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal. Biochem. 216, 276-284.
2. Aguirre Ghiso, J., Kovalski, K., and Ossowski, L. (1999). Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. 147, 89-104.
3. Baker, M. S., Liang, X. M., and Doe, W. F. (1992). Occupancy of the cancer cell urokinase receptor (uPAR): effects of acid elution and exogenous uPA on cell surface urokinase (uPA). Biochim. Biophys. Acta 1117, 143-152.
4. Beaufort, N., Leduc, D., Rousselle, J. C., Magdolen, V., Luther, T., Namane, A., Chignard, M., and Pidard, D. (2004). Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J. Immunol. 172, 540-549.
5. Behrendt, N., Ploug, M., Patthy, L., Houen, G., Blasi, F., and Dano, K. (1991). The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J. Biol. Chem. 266, 7842-7847.
6. Bernstein, A. M., Greenberg, R. S., Taliana, L., and Masur, S. K. (2004). Urokinase anchors uPAR to the actin cytoskeleton. Invest. Ophthalmol. Vis. Sci. 45, 2967-2977.
7. Blasi, F., and Carmeliet, P. (2002). uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 3, 932-943.
8. Carrington, L. M., Albon, J., Anderson, I., Kamma, C., and Boulton, M. (2006). Differential regulation of key stages in early corneal wound healing by TGF-beta isoforms and their inhibitors. Invest. Ophthalmol. Vis. Sci. 47, 1886-1894.
9. Czekay, R. P., Aertgeerts, K., Curriden, S. A., and Loskutoff, D. J. (2003). Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J. Cell Biol. 160, 781-791.
10. Czekay, R. P., Kuemmel, T. A., Orlando, R. A., and Farquhar, M. G. (2001). Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol. Biol. Cell 12, 1467-1479.
11. Degryse, B., Orlando, S., Resnati, M., Rabbani, S. A., and Blasi, F. (2001). Urokinase/urokinase receptor and vitronectin/alpha(v) beta(3) integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways. Oncogene 20, 2032-2043.
12. Desmouliere, A., Darby, I. A., and Gabbiani, G. (2003). Normal and pathologic soft tissue remodeling: role of the myofibroblast, with special emphasis on liver and kidney fibrosis. Lab. Invest. 83, 1689-1707.
13. Desmouliere, A., Redard, M., Darby, I., and Gabbiani, G. (1995). Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am. J. Pathol. 146, 56-66.
14. Dumler, I., Kopmann, A., Weis, A., Mayboroda, O., Wagner, K., Gulba, D., and Haller, H. (1999). Urokinase activates the Jak/Stat signal transduction pathway in human vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 19, 290-297.
15. Dumler, I., Weis, A., Mayboroda, O., Maasch, C., Jerke, U., Haller, H., and Gulba, D. (1998). The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J. Biol. Chem. 273, 315-321.
16. Gabbiani, G. (2003). The myofibroblast in wound healing and fibrocontractive diseases. J. Pathol. 200, 500-503.
17. Garwicz, D., Lindmark, A., and Gullberg, U. (1995). Human cathepsin G lacking functional glycosylation site is proteolytically processed and targeted for storage in granules after transfection to the rat basophilic/mast cell line RBL or the murine myeloid cell line 32D. J. Biol. Chem. 270, 28413-28418.
18. Gyetko, M. R., Todd, R. F., 3rd, Wilkinson, C. C., and Sitrin, R. G. (1994). The urokinase receptor is required for human monocyte chemotaxis in vitro. J. Clin. Invest. 93, 1380-1387.
19. Hinz, B., and Gabbiani, G. (2003). Mechanisms of force generation and transmission by myofibroblasts. Curr. Opin. Biotechnol. 14, 538-546.
20. Hoyer-Hansen, G., Behrendt, N., Ploug, M., Dano, K., and Preissner, K. T. (1997). The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett. 420, 79-85.
21. Hoyer-Hansen, G., Ronne, E., Solberg, H., Behrendt, N., Ploug, M., Lund, L. R., Ellis, V., and Dano, K. (1992). Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J. Biol. Chem. 267, 18224-18229.
22. Jester, J. V., Barry-Lane, P. A., Petroll, W. M., Olsen, D. R., and Cavanagh, H. D. (1997). Inhibition of corneal fibrosis by topical application of blocking antibodies to TGF beta in the rabbit. Cornea 16, 177-187.
23. Jester, J. V., Huang, J., Barry-Lane, P. A., Kao, W. W., Petroll, W. M., and Cavanagh, H. D. (1999). Transforming growth factor(beta)-mediated corneal myofibroblast differentiation requires actin and fibronectin assembly. Invest. Ophthalmol. Vis. Sci. 40, 1959-1967.
24. Jester, J. V., Petroll, W. M., Barry, P. A., and Cavanagh, H. D. (1995). Expression of alpha-smooth muscle (alpha-SM) actin during corneal stromal wound healing. Invest. Ophthalmol. Vis. Sci. 36, 809-819.
25. Kanemaru, K., Meckelein, B., Marshall, D. C., Sipe, J. D., and Abraham, C. R. (1996). Synthesis and secretion of active alpha 1-antichymotrypsin by murine primary astrocytes. Neurobiol. Aging 17, 767-771.
26. Kiian, I., Tkachuk, N., Haller, H., and Dumler, I. (2003). Urokinase-induced migration of human vascular smooth muscle cells requires coupling of the small GTPases RhoA and Rac1 to the Tyk2/PI3-K signalling pathway. Thromb. Haemost. 89, 904-914.
27. Kiyan, J., Kiyan, R., Haller, H., and Dumler, I. (2005). Urokinase-induced signaling in human vascular smooth muscle cells is mediated by PDGFR-beta. EMBO J. 24, 1787-1797.
28. Koshelnick, Y., Ehart, M., Hufnagl, P., Heinrich, P. C., and Binder, B. R. (1997). Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J. Biol. Chem. 272, 28563-28567.
29. Liu, D., Aguirre Ghiso, J., Estrada, Y., and Ossowski, L. (2002). EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1, 445-457.
30. Maguen, E., Zorapapel, N. C., Zieske, J. D., Ninomiya, Y., Sado, Y., Kenney, M. C., and Ljubimov, A. V. (2002). Extracellular matrix and matrix metalloproteinase changes in human corneas after complicated laser-assisted in situ keratomileusis (LASIK). Cornea 21, 95-100.
31. Maltseva, O., Petridou, S., and Masur, S. K. (1998). Cytokine regulation of corneal fibroblast and myofibroblast phenotypes. Invest. Ophthalmol. Vis. Sci. 39, S775.
32. Masur, S. K., Cheung, J. K., and Antohi, S. (1993). Identification of integrins in cultured corneal fibroblasts and in isolated keratocytes. Invest. Ophthalmol. Vis. Sci. 34, 2690-2698.
33. Mazzieri, R., D'Alessio, S., Kenmoe, R. K., Ossowski, L., and Blasi, F. (2006). An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration. Mol. Biol. Cell 17, 367-378.
34. Mohan, R. R., Hutcheon, A. E., Choi, R., Hong, J., Lee, J., Ambrosio, R., Jr., Zieske, J. D., and Wilson, S. E. (2003). Apoptosis, necrosis, proliferation, and myofibroblast generation in the stroma following LASIK and PRK. Exp. Eye Res. 76, 71-87.
35. Moller-Pedersen, T., Cavanagh, H. D., Petroll, W. M., and Jester, J. V. (1998). Neutralizing antibody to TGFbeta modulates stromal fibrosis but not regression of photoablative effect following PRK. Curr. Eye Res. 17, 736-747.
36. Montuori, N., Carriero, M. V., Salzano, S., Rossi, G., and Ragno, P. (2002). The cleavage of the urokinase receptor regulates its multiple functions. J. Biol. Chem. 277, 46932-46939.
37. Montuori, N., Rossi, G., and Ragno, P. (1999). Cleavage of urokinase receptor regulates its interaction with integrins in thyroid cells. FEBS Lett. 460, 32-36.
38. Montuori, N., Visconte, V., Rossi, G., and Ragno, P. (2005). Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? Thromb. Haemost. 93, 192-198.
39. Nakayasu, K. (1988). Stromal changes following removal of epithelium in rat cornea. Jpn. J. Ophthalmol. 32, 113-125.
40. Netto, M. V., Mohan, R. R., Ambrosio, R., Jr., Hutcheon, A. E., Zieske, J. D., and Wilson, S. E. (2005). Wound healing in the cornea: a review of refractive surgery complications and new prospects for therapy. Cornea 24, 509-522.
41. Nykjaer, A., Conese, M., Christensen, E. I., Olson, D., Cremona, O., Gliemann, J., and Blasi, F. (1997). Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J. 16, 2610-2620.
42. Owen, C. A., and Campbell, E. J. (1998). Angiotensin II generation at the cell surface of activated neutrophils: novel cathepsin G-mediated catalytic activity that is resistant to inhibition. J. Immunol. 160, 1436-1443.
43. Ploug, M., Ellis, V., and Dano, K. (1994). Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry 33, 8991-8997.
44. Ragno, P. (2006). The urokinase receptor: a ligand or a receptor? Story of a sociable molecule. Cell Mol. Life Sci. 63, 1028-1037.
45. Shah, M., Foreman, D. M., and Ferguson, M. W. (1992). Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta. Lancet 339, 213-214.
46. Stefansson, S., and Lawrence, D. A. (2003). Old dogs and new tricks: proteases, inhibitors, and cell migration. Sci. STKE 2003, pe24.
47. Stoppelli, M. P., Tacchetti, C., Cubellis, M. V., Corti, A., Hearing, V. J., Cassani, G., Appella, E., and Blasi, F. (1986). Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell 45, 675-684.
48. Thom, S. B., Myers, J. S., Rapuano, C. J., Eagle, R. C., Jr., Siepser, S. B., and Gomes, J. A. (1997). Effect of topical anti-transforming growth factor-beta on corneal stromal haze after photorefractive keratectomy in rabbits. J. Cataract Refract. Surg. 23, 1324-1330.
49. Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., and Brown, R. A. (2002). Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell Biol. 3, 349-363.
50. Tripathi, R. C., Tripathi, B. J., and Park, J. K. (1990). Localization of urokinase-type plasminogen activator in human eyes: an immunocytochemical study. Exp. Eye. Res. 51, 545-552.
51. Twining, S. S., Fukuchi, T., Yue, B. Y., Wilson, P. M., and Zhou, X. (1994). Alpha 1-antichymotrypsin is present in and synthesized by the cornea. Curr. Eye Res. 13, 433-439.
52. Twining, S. S., Zhou, X., Schulte, D. P., Wilson, P. M., Fish, B., and Moulder, J. (1996). Effect of vitamin A deficiency on the early response to experimental Pseudomonas keratitis. Invest. Ophthalmol. Vis. Sci. 37, 511-522.
53. Waltz, D. A., Natkin, L. R., Fujita, R. M., Wei, Y., and Chapman, H. A. (1997). Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J. Clin. Invest. 100, 58-67.
54. Warejcka, D. J., Vaughan, K. A., Bernstein, A. M., and Twining, S. S. (2005). Differential conversion of plasminogen to angiostatin by human corneal cell populations. Mol. Vis. 11, 859-868.
55. Webb, D. J., Nguyen, D. H., Sankovic, M., and Gonias, S. L. (1999). The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro. J. Biol. Chem. 274, 7412-7420.
56. Wei, Y., Lukashev, M., Simon, D. I., Bodary, S. C., Rosenberg, S., Doyle, M. V., and Chapman, H. A. (1996). Regulation of integrin function by the urokinase receptor. Science 273, 1551-1555.
57. Weimar, V. (1957). The transformation of corneal stromal cells to fibroblasts in corneal wound healing. Am. J. Opthalmol. 44, 173-182.
58. Whitelock, R. B., Fukuchi, T., Zhou, L., Twining, S. S., Sugar, J., Feder, R. S., and Yue, B. Y. (1997). Cathepsin G, acid phosphatase, and alpha 1-proteinase inhibitor messenger RNA levels in keratoconus corneas. Invest. Ophthalmol. Vis. Sci. 38, 529-534.
59. Zimmerman, M., Quigley, J. P., Ashe, B., Dorn, C., Goldfarb, R., and Troll, W. (1978). Direct fluorescent assay of urokinase and plasminogen activators of normal and malignant cells: kinetics and inhibitor profiles. Proc. Natl. Acad. Sci. USA 75, 750-753.